Inve India ▾
TATARSONS

Tarsons Products Q1 FY26 results (Apr–Jun 2025) and concall

Healthcare · Concall AI · Call held 12 Aug 2025

Tarsons Products reported an 8% YoY consolidated revenue growth to INR 91 crores in Q1 FY26, driven by a 12% growth in the domestic market. Standalone EBITDA saw a significant 31% YoY increase to INR 22 crores, with margins expanding to 31.2%. However, consolidated PAT declined due to higher depreciation from the newly capitalized Panchla facility. The company faces headwinds in the overseas market due to soft demand and new US tariffs, while domestic competition remains intense, preventing price increases despite green shoots of recovery.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26
Revenue99 96 113 91
EBITDA25 30 37 25
Net profit10 5 10 2
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.